[Clinical observation of a new anti-VEGF drugs conbercept for wet age-related macular degeneration].

OBJECTIVE: To observe the efficacy and safety of intravitreal injection of conbercept, a new drugs of VEGFR fusion proteins, on wet age-related macular degeneration (wAMD).

METHODS: To analyze retrospectively the clinical data of 58 patients with wet wAMD, which was diagnosed by examination of ETDRS charts, color fundus photograph, fluorescein angiography (FFA) and optical coherence tomography (OCT), were underwent intravitreal injection conbercept 0.5 mg (0.05 ml of 10 g/L). Follow-up time was 6 to 12 months.Visual acuity (ETDRS charts letter), retinal thickness, leakage of CNV and operative complications before and after the treatment were analyzed.

RESULTS: Conbercept injection therapeutic times were 3-5, the average therapeutic times were 3.05. At the end of the follow-up period, the mean letter of ETDRS charts was 50.20±12.87, increased 26.20 letters (t=2.936, P<0.01). the ETDRS charts improved 15 or more letters in 33 eyes (53.23%), decreased more than 15 letters in 2 eyes (3.23%); the average foveal thickness on OCT images were (223±74) µm after treatment, decreased significantly (t=3.669, P<0.01) ; FFA showed CNV complete closure in 34 eyes (54.84%), partial closure in 23 eyes (37.10%), no change in 5 eyes (8.06%). IOP increased in 2 eyes after treatment and recovered within one week.

CONCLUSIONS: Intravitreal injection of conbercept for wAMD was well tolerated, with an improvement in BCVA, macular edema and leakage of CNV, reduce the risk of rehaemorrhagia.